ArticleKidney international2009
V1/V2 Vasopressin receptor antagonism potentiates the renoprotection of renin-angiotensin system inhibition in rats with renal mass reduction.
Article in Kidney international, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 60 citations in OpenAlex.
- Preservation of kidney function irrelevant of total kidney volume growth rate with tolvaptan treatment in patients with autosomal dominant polycystic kidney disease.Clinical and experimental nephrology · 2021Trial
- A clinical and experimental investigation of liraglutide effects on the brain-kidney axis.Science advances · 2026Article
- Ciliary G-Protein Coupled Receptor Signaling in Polycystic Kidney Disease.International journal of molecular sciences · 2025Review
- Article
- Long-term association between water intake and kidney function in a population at high cardiovascular risk.The journal of nutrition, health & aging · 2024Article
- Water intake, baseline biopsy, and graft function after living donor kidney transplantation.Scientific reports · 2024Article
- Probiotic Formula Ameliorates Renal Dysfunction Indicators, Glycemic Levels, and Blood Pressure in a Diabetic Nephropathy Mouse Model.Nutrients · 2023Article
- Metabolic effects of vasopressin in pathophysiology of diabetic kidney disease.Frontiers in endocrinology · 2023Review
- Cardiac output improvement by pecavaptan: a novel dual-acting vasopressin V1a/V2 receptor antagonist in experimental heart failure.European journal of heart failure · 2021Article
- SGLT2 inhibition increases serum copeptin in young adults with type 1 diabetes.Diabetes & metabolism · 2020Article
- The New Biology of Diabetic Kidney Disease-Mechanisms and Therapeutic Implications.Endocrine reviews · 2020Review
- A Role for Both V1a and V2 Receptors in Renal Heat Stress Injury Amplified by Rehydration with Fructose.International journal of molecular sciences · 2019Article
- Osmoregulation Performance and Kidney Transplant Outcome.Journal of the American Society of Nephrology : JASN · 2019Article
- Vasopressin Increases Urinary AcidificationJournal of the American Society of Nephrology : JASN · 2019Article
- Plasma copeptin as a predictor of kidney disease.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2019Article
- Life with one kidney.Pediatric nephrology (Berlin, Germany) · 2018Review
- The Chronic Kidney Disease Water Intake Trial: Protocol of a Randomized Controlled Trial.Canadian journal of kidney health and disease · 2017Article
- Validation of Surrogates of Urine Osmolality in Population Studies.American journal of nephrology · 2017Article
- Chronic recurrent dehydration associated with periodic water intake exacerbates hypertension and promotes renal damage in male spontaneously hypertensive rats.Scientific reports · 2016Article
- Urine osmolarity and risk of dialysis initiation in a chronic kidney disease cohort--a possible titration target?PloS one · 2014Article
Corrections and comments
- Commented on by
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Blockade of the renin-angiotensin system (RAS), the standard treatment for chronic proteinuric nephropathy, slows but may not halt progression of the disease, particularly when therapy is started late. Because vasopressin may also play a role in the progression of renal disease, we measured the effect of a dual V(1a) and V(2) vasopressin receptor antagonist (RWJ-676070) alone or combined with angiotensin-converting enzyme inhibition or angiotensin II type 1 receptor blockade on proteinuria and renal disease progression during overt nephropathy. Twenty-one days after renal mass reduction, a time of established injury, rats were given vehicle, RWJ-676070, enalapril, losartan, RWJ-676070 plus enalapril, or losartan in drinking water for an additional 39 days. RWJ-676070 returned the blood pressure to pre-treatment levels, which were significantly lower than those in vehicle-treated rats. Enalapril, losartan, and the combined therapies reduced blood pressure to a greater extent. RWJ-676070 afforded a partial antiproteinuric effect, which was enhanced by the addition of enalapril or losartan. Renal functional impairment, and glomerular and tubular changes were partially ameliorated by RWJ-676070; parameters significantly improved with either enalapril or losartan alone and improved to a greater extent with the combined therapies. Our findings suggest that vasopressin receptor antagonists could be of additional therapeutic value in the treatment of chronic proteinuric nephropathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.